Recombinant Delonix regia Alpha-amylase inhibitor DR1
Description
Introduction to Recombinant Delonix regia Alpha-Amylase Inhibitor DR1
Recombinant DR1 is a 16-amino acid peptide (sequence: SGLLMNFGEQHVNVAQ) expressed in heterologous systems such as Escherichia coli and baculovirus-insect cell cultures . It belongs to the plant-derived α-amylase inhibitor family, which targets enzymes like porcine pancreatic α-amylase (PPA) to regulate starch digestion. Its recombinant form enables scalable production for research and potential therapeutic applications.
Key Features
Sequence and Domains
The inhibitor corresponds to residues 1–16 of the native protein. While structural modeling data for DR1 is limited, homologous α-amylase inhibitors typically adopt compact conformations with disulfide bonds stabilizing the active site-binding region .
Production and Purification
Recombinant DR1 is produced via two primary systems:
-
Baculovirus Expression
-
E. coli Expression
Mechanism of α-Amylase Inhibition
While direct kinetic studies on DR1 are sparse, competitive inhibition is inferred from structural analogs like Juglans regia and Urtica dioica extracts, which bind to the enzyme’s active site, blocking substrate access . Competitive inhibitors typically exhibit dose- and time-dependent effects, as seen in similar plant-derived α-amylase inhibitors .
Therapeutic Potential
-
Diabetes Management: α-Amylase inhibitors delay starch hydrolysis, reducing postprandial blood glucose levels .
-
Anti-Obesity Agents: By limiting carbohydrate absorption, DR1 could aid in weight management therapies.
Agricultural Use
-
Pest Control: Plant α-amylase inhibitors are deployed in genetically modified crops to deter insect pests reliant on starch digestion .
Comparative Analysis with Other Inhibitors
Product Specs
Target Background
Q&A
Basic Research Questions
-
What is Recombinant Delonix regia Alpha-amylase inhibitor DR1?
Recombinant Delonix regia Alpha-amylase inhibitor DR1 is a protein derived from the Royal poinciana (Delonix regia) tree that inhibits alpha-amylase activity. The recombinant form is expressed in E. coli expression systems, resulting in a full-length protein of 16 amino acids . It belongs to the class of alpha-amylase inhibitors, which are important tools in studying carbohydrate metabolism and have potential applications in various research fields.
Property Specification Source organism Delonix regia (Royal poinciana) (Poinciana regia) Expression system E. coli Protein length 16 amino acids (full length) Purity >85% (SDS-PAGE) Uniprot No. P86364 Alternative names Alpha-amylase inhibitor DR1 -
What is the amino acid sequence and structural characteristics of DR1?
The amino acid sequence of DR1 is SGLLMNFGEQ HVNVAQ, covering the expression region 1-16 . This small peptide makes it an interesting model for studying minimal peptide inhibitors. When designing experiments to characterize this protein, researchers should consider:
-
The compact nature of the 16-amino acid sequence may affect binding kinetics and specificity
-
Potential structural elements that contribute to inhibitory function
-
The role of specific amino acid residues in enzyme interaction
Methodological approaches for structural characterization might include circular dichroism spectroscopy, NMR analysis, or computational modeling to understand the structure-function relationship of this compact inhibitor.
-
-
What are the optimal storage and handling protocols for DR1 in research settings?
Proper storage and handling are critical for maintaining DR1 activity in research settings. Follow these methodological guidelines:
Storage Condition Recommendation Duration Standard storage -20°C Short-term Extended storage -20°C or -80°C Long-term Working aliquots 4°C Up to one week Freeze-thaw cycles Avoid repeated cycles N/A For maximum stability, researchers should avoid repeated freezing and thawing of samples . When planning long-term studies, consider preparing multiple aliquots at the initial reconstitution to maintain protein integrity throughout the experimental timeline.
-
What is the recommended reconstitution protocol for DR1?
For reconstitution, implement the following methodological approach:
-
Briefly centrifuge the vial before opening to bring contents to the bottom
-
Reconstitute the protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL
-
For long-term storage, add glycerol to a final concentration of 5-50% (50% being standard)
-
Aliquot the reconstituted protein to minimize freeze-thaw cycles
This protocol helps maintain protein integrity and activity for experimental applications. Researchers should validate protein activity after reconstitution using appropriate enzyme inhibition assays to ensure functional integrity is preserved.
-
-
How does DR1 relate to the broader medicinal properties of Delonix regia?
Delonix regia, the source plant for DR1, has been documented to possess various pharmacological activities. While DR1 specifically is an alpha-amylase inhibitor, it is part of the plant's bioactive profile that may contribute to its medicinal applications.
Understanding how DR1 fits within this broader pharmacological profile requires comparative studies between the purified inhibitor and crude plant extracts. Methodological approaches should focus on isolating the specific contributions of DR1 to these observed activities.
